> ## Content Index
> Fetch the complete content index at: https://www.bioreview.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK's Second Lung Cancer Approval Is a Foothold, Not the Payoff
- URL: https://www.bioreview.com/gsks-second-lung-cancer-approval-is-a-foothold-not-the-payoff/
- Published: 2026-11-18T14:07:37.000Z
- Updated: 2026-11-20T11:54:52.000Z
- Description: GSK has two FDA labels from its $10.6 billion Nuvalent purchase in four months. Both sit in previously treated disease, and the first-line trial that justifies the price will not finish until 2029.
- Author: BioReview Admin
- Tags: Pharmaceuticals, Markets

GSK [completed](https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/?ref=bioreview.com) its $10.6 billion acquisition of Nuvalent on July 15\. Four months later it has two US labels from the deal. On Nov 17 the FDA granted accelerated approval to neladalkib, branded Nelkarmi, for previously treated ALK-positive non-small cell lung cancer, after zidesamtinib was [cleared](https://www.fda.gov/drugs/cancer-approvals/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer?ref=bioreview.com) in July for ROS1-positive disease. Fast work for a company with no lung cancer franchise in January. It is also the cheap half of the thesis. Both labels sit in previously treated disease, and the trial that decides whether the price was right is not scheduled to report until the end of 2029.

### A label drawn narrowly

The approval covers adults with locally advanced or metastatic ALK-positive NSCLC who already received either one prior ALK inhibitor consisting of alectinib, or two or more prior ALK inhibitors plus platinum-based chemotherapy. It stops short of first-line disease, where treatment starts and the largest commercial opportunity sits. It holds breakthrough and orphan designations and cleared 10 days ahead of its Nov 27 target date. Because this is an [approval](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk?ref=bioreview.com) under the accelerated pathway, GSK carries a confirmatory obligation, which matters when the pivotal package is single-arm with no randomized control. GSK put the equity value at $10.6 billion and called the two leads potential best-in-class.

### What ALKOVE-1 showed

ALKOVE-1 (NCT05384626) is a single-arm phase I/II study whose efficacy analysis covered 222 previously treated patients. Among 67 whose only prior ALK inhibitor was alectinib, confirmed overall response rate was 49% (95% CI 37 to 62). Among 155 who had two or more prior inhibitors plus chemotherapy, it was 32% (24 to 40). Durability held: 76% of responders in the alectinib-only group had responses lasting six months or more, against 69% in the heavily pretreated group.

The brain data are the distinctive part. In patients with measurable CNS metastases at baseline, intracranial response was 55% (11 of 20), with 25% complete responses, after alectinib alone, and 26% (14 of 53) after two or more inhibitors plus chemotherapy. GSK says the molecule was [designed](https://www.gsk.com/en-gb/media/press-releases/nelkarmi-neladalkib-approved-in-the-us-for-previously-treated-advanced-alk-positive-non-small-cell-lung-cancer/?ref=bioreview.com) for broad coverage of ALK resistance mutations, blood-brain barrier penetration and high selectivity, and notes that ALK-positive patients are often younger and can stay on treatment for years. That is design intent, not comparative proof.

### The tolerability trade

Safety reads like the class: warnings for hepatotoxicity, renal and ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity, with hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy and fatigue the most common reactions. Permanent discontinuation was 5%, most often for liver injury. Permanent discontinuation in lorlatinib's CROWN trial was 6.7%, though different populations in different trials make that a hypothesis, not a finding. In a disease where patients cycle through several inhibitors over years, a tolerability edge can matter as much as a few points of response.

### Lorlatinib's shadow

Nelkarmi arrives behind a well-established competitor. Pfizer's lorlatinib won accelerated [approval](https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc?ref=bioreview.com) in November 2018 in previously treated ALK-positive disease, on a 48% response rate across 215 patients and a 60% intracranial response rate in 89 patients with measurable CNS lesions. It took full approval and a first-line indication in March 2021 on CROWN, which randomized 296 previously untreated patients and cut the risk of progression or death by 72% versus crizotinib (HR 0.28). None of those figures can be lined up against ALKOVE-1: different eras, different prior treatment, single-arm designs in two of the three. Nothing here supports a claim of superiority.

ALK fusions are roughly 3% to 5% of NSCLC, and up to 40% of ALK-positive metastatic patients arrive with brain metastases.

### The 2029 answer

The commercial question is already in the clinic. ALKAZAR (NCT06765109) randomizes about 450 treatment-naive patients 1:1 to neladalkib 150 mg daily or alectinib 600 mg twice daily, with progression-free survival by blinded review as the primary endpoint. Nuvalent designed and started the [trial](https://clinicaltrials.gov/study/NCT06765109?ref=bioreview.com) in July 2025, before GSK owned it. It is still recruiting, with primary completion scheduled for December 2029\. Alectinib is the comparator, so a win would establish superiority over that drug in a first-line field where lorlatinib also holds full approval.

### What the milestone proves

Two approvals in four months from a $10.6 billion check is genuine execution, and for patients who have exhausted alectinib or burned through several inhibitors, a 49% response with intracranial activity is a real option. Both labels sit behind the first-line decision, both rest on single-arm evidence, and the study that carries the deal price is not scheduled to read out until the end of 2029\. The foothold is secured. The payoff is still four years out.